Acelrx Pharmaceuticals Inc RSI
Mi az Acelrx Pharmaceuticals Inc RSI?
A RSI az Acelrx Pharmaceuticals Inc - 45.25
Mi a RSI meghatározása?
A relatív erősségindex (RSI 14) egy olyan impulzusmutató, amely összehasonlítja a nyereségek és veszteségek nagyságát egy meghatározott időtartam alatt a sebesség és az árfolyammozgások változásának mérésére.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI a Health Care szektor a NASDAQ-on cégekben a Acelrx Pharmaceuticals Inc -hoz képest
Mit csinál Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
rsi -hoz hasonló cégek Acelrx Pharmaceuticals Inc
- Baytex nak RSI 45.23 van
- Minco Silver nak RSI 45.24 van
- Alerus Corp nak RSI 45.24 van
- TransAlta Renewables nak RSI 45.24 van
- Cryo-Cell International nak RSI 45.24 van
- NP3 Fastigheter AB (publ) nak RSI 45.24 van
- Acelrx Pharmaceuticals Inc nak RSI 45.25 van
- Clear Blue Technologies International nak RSI 45.26 van
- Geomega Resources nak RSI 45.26 van
- Portman Ridge Finance Corp nak RSI 45.26 van
- Boralex nak RSI 45.27 van
- TUI AG nak RSI 45.27 van
- Insmed Inc nak RSI 45.27 van